 |
|
|
|
Local News
Submit News Release
- Monsanto company declares quarterly dividend Monsanto Company announced that its Board of Directors has declared a quarterly dividend on its common stock of 24 cents per share. The dividend relates to the company's fourth quarter of its 2008 fiscal year.
Monsanto Company August 06, 2008
- Lilly sells its Greenfield, Indiana, operations to Covance Eli Lilly and Company announced that Covance will buy and operate Lilly's Greenfield Laboratories located in Greenfield, Indiana. In addition, Lilly is finalizing plans to lease a new worldwide headquarters for its animal health division, Elanco, in Hancock County, Indiana.
Eli Lilly and Company August 06, 2008
- Monsanto to pursue divestiture of POSILAC Monsanto Company announced that it is pursuing a divestiture of its dairy product, POSILAC(R) bovine somatotropin, in the upcoming months. Additional details have not been disclosed at this time.
Monsanto Company August 06, 2008
- Genzyme and Isis begin second Phase 3 trial of mipomersen Genzyme and Isis Pharmaceuticals announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes exceptionally high levels of LDL cholesterol.
Genzyme Corporation August 06, 2008
- Lipitor 80 mg reduced the risk of heart attack and stroke in patients Pfizer announced that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor(R) (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35 percent compared with Lipitor 10 mg.
Pfizer Inc. August 06, 2008
- Ore Pharmaceuticals acquires rights to develop a second drug candidate from Roche Ore Pharmaceuticals announced that it has acquired from Roche the exclusive development rights for the clinical-stage compound romazarit. Ore Pharmaceuticals had previously identified potentially novel therapeutic uses for romazarit in metabolic diseases.
Ore Pharmaceuticals, Inc. August 06, 2008
- Regeneron announces VelociGene(R) agreement with Sanofi-Aventis Regeneron Pharmaceuticals announced that it has entered into an agreement with sanofi-aventis to use Regeneron's proprietary VelociGene technology platform to supply sanofi-aventis with genetically modified mammalian models of gene function and disease.
Regeneron Pharmaceuticals, Inc. August 05, 2008
- Vanda Pharmaceuticals reports second quarter 2008 results Vanda Pharmaceuticals announced financial and operational results for the second quarter ended June 30, 2008. Vanda reported research and development (R&D) expenses in the second quarter of 2008 of $5.5 million, compared to first quarter of 2008 R&D expenses of $11.1 million.
Vanda Pharmaceuticals Inc. August 05, 2008
- Pharmacopeia announces further reductions to workforce Pharmacopeia has implemented the restructuring noted in its recent quarterly earnings release and conference call. This effort includes an immediate workforce reduction of approximately 40 percent through termination of positions.
Pharmacopeia August 05, 2008
- ISENTRESS(R) reduced HIV viral load and increased CD4 cell counts ISENTRESS(R) (raltegravir), Merck & Co.'s first-in-class integrase inhibitor, in combination with two other anti-HIV medicines, reduced HIV viral load to undetectable levels (less than 50 copies/mL) in 83 percent of previously untreated (treatment-naïve) HIV-infected patients.
Merck & Co., Inc. August 05, 2008
(next 10 articles)
Submit News Release
|
|
|
|
|
|
